Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
暂无分享,去创建一个
Guido Cavaletti | Jordi Bruna | G. Cavaletti | A. Argyriou | P. Marmiroli | J. Bruna | Paola Marmiroli | Andreas A Argyriou
[1] H. Adelsberger,et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. , 2000, European journal of pharmacology.
[2] G Cartei,et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.
[3] P. Hilkens,et al. Chemotherapy-induced peripheral neuropathy. , 1997, Journal of the peripheral nervous system.
[4] E. Henderson,et al. Vincristine‐induced neuropathy , 1969, Neurology.
[5] M. Baccarani,et al. Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma , 2005, European journal of haematology.
[6] P. Dougherty,et al. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. , 2007, Journal of pain and symptom management.
[7] Alan Gordon,et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.
[8] W. Trojaborg,et al. Electrophysiological study of the peripheral and central neurotoxic effect of cis‐platin , 1987, Acta neurologica Scandinavica.
[9] G. Cavaletti,et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.
[10] A. Caraceni,et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale , 2007, Journal of the peripheral nervous system : JPNS.
[11] A. Argyriou,et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. , 2006, Journal of pain and symptom management.
[12] J. Baselga,et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Grothey,et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Yakoub-Agha,et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations , 2010, Haematologica.
[15] J. Crowley,et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Crinò,et al. A Pilot Study on the Effect of Acetyl-L-Carnitine in Paclitaxel-And Cisplatin-Induced Peripheral Neuropathy , 2005, Tumori.
[17] R. Herbst,et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Dearnaley,et al. Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer , 2010, Cancer.
[19] E. Lazarides,et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.
[20] A. Argyriou,et al. A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.
[21] G. Nicolini,et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. , 2005, European journal of cancer.
[22] A. Argyriou,et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer , 2007, Acta oncologica.
[23] C. Liao,et al. Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials , 2010, International Journal of Colorectal Disease.
[24] J. Walewski,et al. CHOP-21 for unfavorable Hodgkin’s lymphoma. An exploratory study , 2010, Medical oncology.
[25] D. Esseltine,et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. , 2006, Blood.
[26] A. Pace,et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[27] E. Vokes,et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Kevin D. Nullmeyer,et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. , 2005, Cancer research.
[29] E. Bandrés,et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis , 2010, British Journal of Cancer.
[30] S. Studenski,et al. Persistent Mobility Disability After Neurotoxic Chemotherapy , 2010, Physical Therapy.
[31] A. Knight,et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity , 2005, Neurobiology of Disease.
[32] S. Agelaki,et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] P. Sonneveld,et al. A practical update on the use of bortezomib in the management of multiple myeloma. , 2006, The oncologist.
[34] C. Sawka,et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Groshen,et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.
[36] G. Cavaletti,et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Glick,et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W. Scheithauer,et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Koltzenburg,et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. , 2008, Critical reviews in oncology/hematology.
[40] H. Earl,et al. Long-Term Neurotoxicity of Chemotherapy in Adolescents and Young Adults Treated for Bone and Soft Tissue Sarcomas , 1998, Sarcoma.
[41] H. Kantarjian,et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[43] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] C. Bokemeyer,et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] D. Fishman,et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[46] R. Mandler,et al. Fulminant demyelinating neuropathy mimicking cerebral death , 1997 .
[47] M. Zucchetti,et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. , 2000, Neurotoxicology.
[48] G. Trovato,et al. [Erythropoietin and cisplatin-induced neuropathies in cancer patients]. , 2002, La Clinica terapeutica.
[49] D. Restuccia,et al. Cisplatin neuropathy: clinical course and neurophysiological findings , 1992, Journal of Neurology.
[50] J. Levine,et al. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine‐induced painful peripheral neuropathy in the rat , 2000, The Journal of comparative neurology.
[51] S. Steinberg,et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. Novotny,et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J J Correia,et al. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. , 1996, Biochemistry.
[54] M. Friedlander,et al. Oxaliplatin-Induced Lhermitte’s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity , 2009, Oncology.
[55] A. Argyriou,et al. Paclitaxel plus carboplatin–induced peripheral neuropathy , 2005, Journal of Neurology.
[56] M. Dimopoulos,et al. Treatment of Waldenstrom’s Macroglobulinemia , 2007, Current treatment options in oncology.
[57] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] C. Tournigand,et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] B. Glimelius,et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] D. Stewart,et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] M. Sereno,et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[62] J. Bogaerts,et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] T. Ruhstaller,et al. Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? , 2010, Supportive Care in Cancer.
[64] P. Rougier,et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study , 2009, PAIN®.
[65] G. Cavaletti,et al. Thalidomide sensory neurotoxicity , 2004, Neurology.
[66] C. Spurr,et al. Treatment of advanced non‐Hodgkin's lymphoma with vincristine infusion , 1984, Cancer.
[67] T. Cosgriff,et al. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. , 2011, Clinical breast cancer.
[68] K. Altmann,et al. Synthesis and biological evaluation of highly potent analogues of epothilones B and D. , 2000, Bioorganic & medicinal chemistry letters.
[69] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[70] K. Savin,et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[71] E. Mamounas,et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] P. Thoumie,et al. How far do patients with sensory ataxia benefit from so-called “proprioceptive rehabilitation”? , 2009, Neurophysiologie Clinique/Clinical Neurophysiology.
[73] E. Perez,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[74] H Irschik,et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. , 1996, The Journal of antibiotics.
[75] D. Sargent,et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.
[76] J. Heimans,et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening , 2005, Neurology.
[77] A. Argyriou,et al. Vitamin E for preventing chemotherapy-induced peripheral neuropathy , 2011, Supportive Care in Cancer.
[78] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[79] M. Floeter,et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] B. Smoller,et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. , 2007, Carcinogenesis.
[81] Krarup,et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study , 1999, Neuropathology and applied neurobiology.
[82] A. Windebank,et al. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. , 1998, The Journal of clinical investigation.
[83] P. Dougherty,et al. Quantitative sensory findings in patients with bortezomib-induced pain. , 2007, The journal of pain : official journal of the American Pain Society.
[84] G. Cavaletti,et al. Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives. , 2009, Mini reviews in medicinal chemistry.
[85] Low-Dose Thalidomide for Multiple Myeloma: Interim Analysis of a Compassionate Use Program , 2004, Oncology Research and Treatment.
[86] J. Heimans,et al. Long term effects of vincristine on the peripheral nervous system , 2005, Journal of Neuro-Oncology.
[87] J. Heimans,et al. A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. , 1992, Archives of neurology.
[88] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] D. Esseltine,et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline , 2009, British journal of haematology.
[90] C. Bokemeyer,et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Jun Liang,et al. Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer , 2010, Journal of Korean medical science.
[92] K. Swenerton,et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] A. Zelenetz,et al. A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma , 2008, British journal of haematology.
[94] T. Bird,et al. Severe vincristine neuropathy in charcot‐marie‐tooth disease type 1A , 1996 .
[95] J. C. Houwelingen,et al. Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990 .
[96] H. Reichenbach,et al. New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. , 2001, Journal of natural products.
[97] H. Diener,et al. Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma , 2004, Journal of Cancer Research and Clinical Oncology.
[98] Diane Warren,et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.
[99] H. Groen,et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial , 2003, British Journal of Cancer.
[100] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] E. Alba,et al. 'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[102] D. Berry,et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] D. Esseltine,et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] P. Ott,et al. A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma , 2010, PloS one.
[105] G. Cavaletti,et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.
[106] H. Gelderblom,et al. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. , 2005, Cancer treatment reviews.
[107] Michael L. Wang,et al. Multiple Myeloma, Painful Neuropathy, Acupuncture? , 2009, American journal of clinical oncology.
[108] S. Steinberg,et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer , 2006, Investigational New Drugs.
[109] H. Chung,et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.
[110] M. Friedlander,et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. , 2009, Brain : a journal of neurology.
[111] T. Miyazaki,et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study , 2010, International Journal of Clinical Oncology.
[112] D. Esseltine,et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] M. Loriot,et al. Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy , 2006, Clinical Cancer Research.
[114] A. Ranganathan,et al. Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. , 2006, Clinical colorectal cancer.
[115] L. Padua,et al. Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity , 2006, Journal of the peripheral nervous system : JPNS.
[116] D. Cornblath,et al. Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy , 2008, Journal of the peripheral nervous system : JPNS.
[117] R. Gascoyne,et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma , 2009, Cancer.
[118] T. Boulikas. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. , 2004, Oncology reports.
[119] M. Friedlander,et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. , 2008, Current medicinal chemistry.
[120] Charles W. Taylor,et al. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer , 2004, Breast Cancer Research and Treatment.
[121] D. Lake,et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. , 2010, Clinical breast cancer.
[122] D. Crowther,et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. , 1990, Annals of Oncology.
[123] A. Argyriou,et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. , 2007, European journal of cancer care.
[124] O. Dalesio,et al. Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement , 1990, Journal of Neuro-Oncology.
[125] M. Kelley,et al. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. , 2008, Cancer research.
[126] A. Argyriou,et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. , 2008, Blood.
[127] A. Palumbo,et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features , 2004, Acta neurologica Scandinavica.
[128] A. Windebank,et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. , 2006, Neurotoxicology.
[129] M. Ermani,et al. Thalidomide neurotoxicity , 2004, Neurology.
[130] J. Shafer,et al. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. , 1992, Biochemistry.
[131] G. Sutton,et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.
[132] D. Cella,et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] J. Manola,et al. Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) , 2007, Cancer.
[134] J. Rogin,et al. Peripheral sensory neuropathy and cisplatin chemotherapy , 1984, Neurology.
[135] A. Silvani,et al. Vitamin E neuroprotection for cisplatin neuropathy , 2010, Neurology.
[136] J. Sloan,et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial , 2011, Supportive Care in Cancer.
[137] K. Kitagawa,et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. , 2010, International journal of clinical pharmacology and therapeutics.
[138] D Grob,et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. , 1973, Cancer research.
[139] M. J. van den Bent,et al. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. , 2002, European journal of cancer.
[140] A. Argyriou,et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? , 2006, Supportive Care in Cancer.
[141] F. Matsuda,et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. , 2010, Cancer epidemiology.
[142] S. Steinberg,et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] E K Rowinsky,et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] R. Eeles,et al. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. , 1986, Cancer treatment reports.
[145] T. Aoki,et al. Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer , 2003, Cancer Chemotherapy and Pharmacology.
[146] Jin-Hwang Liu,et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. , 2007, The oncologist.
[147] Wolfgang Grisold,et al. Chemotherapy‐induced neuropathy , 2008, Journal of the peripheral nervous system : JPNS.
[148] M. Rocchi,et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[149] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[150] Sindhu Ramchandren,et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia , 2009, Journal of the peripheral nervous system : JPNS.
[151] J. Albanell,et al. The proteasome: a novel target for anticancer therapy , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[152] G. Pond,et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. , 2003, Lung cancer.
[153] J. Gralow,et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. , 2008, Clinical breast cancer.
[154] S. Swain,et al. Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] A. Windebank,et al. Cisplatin-Induced Apoptosis of DRG Neurons Involves Bax Redistribution and Cytochrome c Release But Not fas Receptor Signaling , 2002, Neurobiology of Disease.
[156] J. Crowley,et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[157] S. Brady,et al. Axonal tubulin and microtubules: morphologic evidence for stable regions on axonal microtubules. , 1987, Cell motility and the cytoskeleton.
[158] J. Heimans,et al. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer , 2003, Journal of Neuro-Oncology.
[159] R. Labianca,et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[160] P. Giannakakou,et al. Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)* , 1997, The Journal of Biological Chemistry.
[161] A. Argyriou,et al. The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy. , 2007, The oncologist.
[162] P. M. L. Quesne,et al. Vincristine neuropathy. Clinical and electrophysiological observations. , 1973, Brain : a journal of neurology.
[163] C. Punt,et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. , 2009, European journal of cancer.
[164] R. Donehower,et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies , 1994, Annals of neurology.
[165] G. Cavaletti,et al. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat , 2007, Experimental Neurology.
[166] J. Verweij,et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands , 2000, Anti-Cancer Drugs.
[167] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[168] G. Bennett,et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells , 2008, Experimental Neurology.
[169] S. Rossi,et al. Thalidomide-induced neuropathy: A ganglionopathy? , 2003, Neurology.
[170] A. Argyriou,et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy , 2006, Neurology.
[171] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[172] M. Fukuoka,et al. A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma , 1991, Cancer.
[173] C. Bokemeyer,et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[174] I. Judson,et al. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. , 1991, British Journal of Cancer.
[175] G. Cavaletti,et al. Chemotherapy-induced peripheral neurotoxicity , 2004, Expert opinion on drug safety.
[176] M. Floeter,et al. Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy , 2004, Muscle & nerve.
[177] J. Baselga,et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[178] J. Blessing,et al. A Phase II Trial of Vincristine in Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study , 1993, American journal of clinical oncology.
[179] C. Leonetti,et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[180] M. Leandri,et al. Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up , 2006, European Neurology.
[181] J. Kopec,et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[182] J. Slingerland,et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer , 2010, Breast Cancer Research and Treatment.
[183] H. Kaube,et al. Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy , 2007, The Journal of Neuroscience.
[184] R. Ramlau,et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[185] P. Bouche,et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. , 2002, The Journal of investigative dermatology.
[186] M. Spira,et al. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy , 2010, Acta Neuropathologica.
[187] H. Gómez,et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[188] P. Mantyh,et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat , 2007, Brain Research.
[189] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[190] T. Boulikas,et al. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). , 2007, Anticancer research.
[191] L. Deangelis,et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non‐hodgkin's lymphoma , 1991, Cancer.
[192] Xavier Navarro,et al. Neurological monitoring reduces the incidence of bortezomib‐induced peripheral neuropathy in multiple myeloma patients , 2010, Journal of the peripheral nervous system : JPNS.
[193] C. Tournigand,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[194] C. Higano,et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel , 2007, Investigational New Drugs.
[195] J. Lotz,et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.
[196] G. Cavaletti,et al. Bortezomib‐induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats , 2010, European journal of pain.
[197] A. Lissoni,et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale , 2003, Neurology.
[198] L. Davis,et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.
[199] P. Dyck,et al. Vinca alkaloid neuropathy , 1968, Neurology.
[200] J. Holland,et al. Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD , 1992, Cancer.
[201] D. Rosenthal,et al. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced‐stage Hodgkin's disease , 1989, Cancer.
[202] J. Minna,et al. Possible enhancement of vincristine neuropathy by VP‐16 , 1982, Cancer.
[203] A. Valachis,et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. , 2010, Cancer treatment reviews.
[204] N. Petrelli,et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[205] S. Culine,et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.
[206] H. Reinders-Messelink,et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. , 2000, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[207] T. Fojo,et al. A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.
[208] A. Troxel,et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).
[209] D. Strumberg,et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[210] J. Mendell,et al. Studies on the pathogenesis of vincristine‐induced neuropathy , 1987, Muscle & nerve.
[211] A. Argyriou,et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy , 2005, Neurology.
[212] A. Argyriou,et al. Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? , 2010, European journal of neurology.
[213] J. Glass,et al. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity , 2008, Cancer Chemotherapy and Pharmacology.
[214] J. Albers,et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2014, The Cochrane database of systematic reviews.
[215] M. Socinski,et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[216] R. Penny,et al. Vincristine neuropathy: an electrophysiological and histological study. , 1969, Journal of neurology, neurosurgery, and psychiatry.
[217] T. Boulikas,et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.
[218] J. Levine,et al. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine‐induced painful neuropathy in rat , 1998, The Journal of comparative neurology.
[219] J. Gilsbach,et al. Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. , 2007, Journal of neurosurgery. Spine.
[220] H. Dombret,et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.
[221] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[222] W. Figg,et al. Thalidomide metabolism and hydrolysis: mechanisms and implications. , 2006, Current drug metabolism.
[223] G. Cavaletti,et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. , 2001, European journal of cancer.
[224] J. Sparano,et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] G. Cavaletti,et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. , 1997, Neurotoxicology.
[226] M. Berciano,et al. Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons , 2010, Neurotoxicity Research.
[227] A. Rapoport,et al. Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature , 2007, Cancer.
[228] J. Schellens,et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin , 2009, Acta oncologica.
[229] E. Gamelin,et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. , 2001, Journal of neurophysiology.
[230] D. Cella,et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[231] F. Goldwasser,et al. Exacerbation of oxaliplatin neurosensory toxicity following surgery. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[232] M. Friedlander,et al. Oxaliplatin‐induced neurotoxicity and the development of neuropathy , 2005, Muscle & nerve.
[233] G. Cavaletti,et al. Carboplatin toxic effects on the peripheral nervous system of the rat. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[234] X. Navarro,et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice , 2010, Experimental Neurology.
[235] M. Miloso,et al. Role of MAPKs in platinum-induced neuronal apoptosis. , 2009, Neurotoxicology.
[236] Roy E. Furman,et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721 , 1988, Cancer.
[237] G. Cavaletti,et al. Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity , 1992, Cancer.
[238] D. Crowther,et al. Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma , 1990 .
[239] Howard L McLeod,et al. Platinum neurotoxicity pharmacogenetics , 2009, Molecular Cancer Therapeutics.
[240] R. Burger,et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[241] J. Lacy,et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[242] R. G. van der Hoop,et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin , 1990, Cancer.
[243] G. Cavaletti,et al. Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity , 2008, Journal of the peripheral nervous system : JPNS.